All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Brucellosis, caused by bacteria of the genus Brucella, is a major zoonosis worldwide. Although it has been well controlled in most developed countries, brucellosis is still endemic in Africa, Asia, the Middle East, the Mediterranean and South America \[[@pone.0205500.ref001], [@pone.0205500.ref002]\]. Human brucellosis is a major public health problem that has re-emerged in China since the mid-1990s, with the highest recorded number of cases (56,989 cases) in 2015 \[[@pone.0205500.ref003]--[@pone.0205500.ref005]\]. This may be due to the dynamic growth of animal husbandry in China, which enhances the chance of human infection. Moreover, the national infectious disease surveillance system has reported an increased rate of human brucellosis \[[@pone.0205500.ref006]\].

The disease is spread to humans mainly by the ingestion of infected meat or unpasteurized dairy products, by contact with infected animals or inhalation of infectious aerosolized particles \[[@pone.0205500.ref007]\]. Brucellosis usually leads to protean manifestation and may have polymorphic features affecting any organ system. The diagnosis of brucellosis is challenging because unusual presentations and non-specific symptoms can lead to misdiagnosis and treatment delay. Although the mortality rate is low, brucellosis can be severely debilitating and disabling \[[@pone.0205500.ref008], [@pone.0205500.ref009]\]. A timely and accurate diagnosis is key to the clinical management of brucellosis. There is an urgent need for an increased awareness of the clinical characteristics of brucellosis among physicians.

Between 2000 and 2012, research into the clinical characteristics of brucellosis was done in Turkey \[[@pone.0205500.ref010]\], Iran \[[@pone.0205500.ref011]\], Greece \[[@pone.0205500.ref012]\] and Saudi Arabia \[[@pone.0205500.ref013]\]. But the results differed between studies. This may be due to small sample sizes or different methods for case classification. In order to reliably examine the clinical characteristics of brucellosis, the series used in the present study is larger than that used in previous studies, and a common case classification is used.

Reliable data on the clinical characteristics of human brucellosis should improve the identification of relevant prognostic factors and improve the clinical management of this debilitating condition. This study aims to describe the symptoms, signs and laboratory findings of 2041 hospitalized patients with laboratory confirmed brucellosis, and assess the risk factors for their clinical outcomes.

Methods {#sec006}
=======

Setting {#sec007}
-------

The Sixth People\'s Hospital of the Xinjiang Uygur Autonomous Region (hereafter called the Sixth People's Hospital) is a tertiary infectious disease specialist hospital with 11 clinical departments and 460 beds. As an important referral center, the hospital approximately reported 27% of total reported brucellosis cases in Xinjiang yearly. A total of 2041 patients with laboratory-confirmed brucellosis were admitted to the hospital between January 1^st^ and December 31^st^ of 2014 and were included in this retrospective study. We accessed patient medical records from March 12^th^ to early April 2016 and performed telephone interviews in late April 2016. The patient files were examined using a standardized form, which recorded demographic data, medical history, clinical and laboratory findings, any antibiotic treatment, and any focal involvements.

Case definition {#sec008}
---------------

A confirmed case of brucellosis was defined as a patient with compatible clinical symptoms (such as arthralgia, fever, sweating, chills, headache, myalgia, malaise) and laboratory evidence of Brucella infection diagnosed by bacteria culture or SAT (≥1:200). Based on the duration of the systemic disease before admission to hospital, patients were divided into three groups: acute brucellosis (\<2 months), subacute brucellosis (2--12 months), and chronic brucellosis (\>12 months). All cases underwent routine laboratory tests.

Treatment and follow-up {#sec009}
-----------------------

Patients were treated with various combinations of antibiotics. The antibiotics regimens were given on the basis of China's Practice Guideline for brucellosis diagnosis and treatment \[[@pone.0205500.ref014]\]: doxycycline (100mg every 12 h), rifampin (600 -900mg every 24 h), intramuscular streptomycin (15mg/kg every 24 h), levofloxacin (200mg every 12 h), ciprofloxacin (750mg every 12 h), and co-trimoxazole (960mg every 12 h). For children under 8 years of age and pregnant women, only rifampin (600-900mg every 24 h) was provided. Given the effectiveness of previous treatment and patient compliance (Xinjiang's vast land posed a challenge to subsequent patient visits), the treatment duration was extended to 3--6 months for all patients. The outcome of treatment (including medication compliance and symptom recovery) was investigated by telephone interview. Admittedly telephone interview is not the ideal method of follow-up, but since in chronic/ persisting brucellosis the symptoms are often subjective and telephone interview allowed for a larger enrollment of patients in follow-up, we considered this to be an acceptable follow-up method.

Data analysis {#sec010}
-------------

Data were entered into Epidata (version 2.0, Odense, Denmark). Medians and interquartile ranges (IQRs) were calculated for continuous variables, and compared between different groups using the Wilcoxon rank sum test. For categorical variables, case frequencies in each category were compared using a Chi-square test or Fisher's exact test. For multiple comparisons, the Bonferroni correction was applied. To further examine the association between potential risk factors and treatment outcome, we first performed univariate analysis. For multivariable logistic regression, we included variables with *p\<*0.05 in univariate analysis or those believed to be potential risk factors associated with the outcome. The software program SAS 9.3 and R 3.3.1 were used to analyze the data.

Ethical approval {#sec011}
----------------

Ethical approval (no. 201533) was obtained from the Institutional Review Board (IRB) of China CDC before the survey began. With IRB's ratification, we signed a confidentiality agreement with the hospital to use patient medical records for research purposes. We confirmed that all participant identifying information (including patient names, ID numbers, home addresses and telephone numbers) would not be included in recordings, written descriptions or publications. Because written informed consent is difficult to obtain during a telephone survey, the use of verbal informed consent was approved by the IRB for this retrospective study. Verbal informed consent was obtained from all respondents over the phone and documented in forms. For subjects younger than 17 years of age, we obtained verbal consent from their parents or legal guardians.

Results {#sec012}
=======

A total of 2586 patient files (including 2757 hospitalization records) were investigated for the purpose of this study. For patients who were hospitalized more than once between January 1^st^ and December 31^st^ of 2014, only their first hospitalization records were evaluated. A total of 2041 laboratory confirmed cases met the case definition and inclusion criteria and were included in this study (see [Fig 1](#pone.0205500.g001){ref-type="fig"}). The median age of the 2041 cases was 43 years (IQR 21--52) and 77% were male. A total of 1141 patients (56%) were aged between 25--49 years and 529 (26%) were aged between 50--64 years. The age distribution was significantly different between acute, subacute and chronic patients, *p =* 0.001. Most (87%) patients under 15 years-old presented as acute cases. Of 2041 cases, 90% were from rural areas, 84% were farmers or herders, 97% had a history of animal exposure and 1.8% ingested unpasteurized foods. For patients whose first contact health sector was the Sixth People's Hospital, the median number of days from illness onset to diagnosis was 12 days (IQR 7--28) in acute cases, 92 days (IQR 68--129) in subacute cases and 410 days (IQR 369--784) in chronic cases ([Table 1](#pone.0205500.t001){ref-type="table"}).

![Flowchart for enrollment of 2041 brucellosis confirmed cases in Xinjiang, China, 2014.](pone.0205500.g001){#pone.0205500.g001}

10.1371/journal.pone.0205500.t001

###### Demographic features and exposure history of 2041 brucellosis cases, Xinjiang, China, 2014.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                      Acute\       Subacute\      Chronic\        Total\       *p*[\*](#t001fn003){ref-type="table-fn"}
                                                                       (N = 1520)   (N = 446)      (N = 75)        (N = 2041)   
  -------------------------------------------------------------------- ------------ -------------- --------------- ------------ ------------------------------------------
  Demographic features                                                                                                          

  Male sex                                                             1180 (78)    338 (76)       55 (73)         1573 (77)    0.53

  Age group (years)                                                                                                             

      \<4                                                              36 (2)       5 (1)          \-              41 (2)       0.001

      5--14                                                            63 (4)       10 (2)         \-              73 (4)       

      15--24                                                           115 (8)      32 (7)         2 (3)           149 (7)      

      25--49                                                           871 (57)     229 (51)       41 (55)         1141 (56)    

      50--64                                                           362 (24)     139 (31)       28 (37)         529 (26)     

      ≥65                                                              72 (5)       32 (7)         4 (5)           108 (5)      

  From                                                                                                                          

      Urban                                                            150 (10)     52 (12)        8 (11)          210 (10)     0.55

      Rural                                                            1370 (90)    394 (88)       67 (89)         1831 (90)    

  Occupation                                                                                                                    

      Farmer& herdman                                                  1276 (84)    373 (84)       64 (85)         1713 (84)    0.30

      Student                                                          67 (4.4)     16 (3.6)       \-              83 (4.1)     

      Preschool children                                               46 (3.0)     8 (1.8)        \-              54 (2.7)     

      Veterinarian                                                     37 (2.4)     9 (2.0)        5 (6.7)         51 (2.5)     

      Other occupation                                                 244 (16)     73 (16)        11 (15)         328 (16)     

  Exposure history                                                                                                              

  Animals exposure                                                     1479 (97)    431(97)        71 (96)         1981 (97)    0.52

      Sheep & goats                                                    1465 (96)    427 (96)       71 (95)         1963 (96)    0.92

      Cattle                                                           1356 (89)    382 (86)       63 (84)         1801 (88)    0.30

      Other animals[\*](#t001fn003){ref-type="table-fn"}               11 (0.7)     6 (1)          1 (1)           18 (0.9)     0.08

      Unknown                                                          42 (3)       14 (3)         3 (4)           60 (3)       0.77

  Method of exposures to animals                                                                                                

      Raising                                                          1401 (92)    401 (90)       63 (84)         1865 (91)    0.08

      Delivering lambs                                                 934 (61)     298 (67)       56 (75)         1288 (63)    0.04

      Slaughter                                                        410 (27)     145 (33)       26 (35)         581 (28)     0.14

      Others routes[\*\*](#t001fn004){ref-type="table-fn"}             70 (5)       25 (6)         13 (17)         108 (5)      \<0.0001

  Ingestion of\                                                        23 (1.5)     13 (3)         1 (1)           37 (1.8)     0.20
  unpasteurized food                                                                                                            

  Days from onset to diagnosis[^†^](#t001fn002){ref-type="table-fn"}   12 (7--28)   92 (68--129)   410(369--784)   15 (7--33)   \-

  Duration of hospitalization (days)                                   12 (9--14)   13 (10--15)    13 (10--15)     12 (9--14)   0.07
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are no. (%) of case, unless otherwise indicated. Percentages may not total 100 because of rounding. IQR, inter quartile range.

†Only 432 acute cases, 65 subacute cases and 9 chronic cases whose first contact health sector was the Sixth People's Hospital were enrolled for analysis. Patients who were referred to the current hospital and diagnosed at other hospitals were not included.

\*Other animals include pigs, dogs, horses, deer and camels.

\*\*Other routes include veterinarian, vaccine producing, animal trade, animal product processing and sheep clipping.

Clinical presentation {#sec013}
---------------------

[Table 2](#pone.0205500.t002){ref-type="table"} lists the main symptoms and signs on presentation. Based on the systemic disease duration before admission to hospital, 1520 (74%) cases were evaluated as acute, 446 (22%) cases as subacute and 75 (4%) as chronic ([Fig 1](#pone.0205500.g001){ref-type="fig"}). The most common symptoms on presentation were fatigue (67%), arthralgia (63%), sweating (54%), back pain (37%) and lack of appetite (25%). The most common signs were fever (64%), splenomegaly (42%), hepatomegaly (24%) and weight loss (19%). In a comparison of different clinical groups, fever, splenomegaly, lack of appetite and cough were more common in acute cases (68%, 45%, 27%, 12%, respectively) than in subacute (56%, 36%, 19%, 5%, respectively, adjusted *p*\<0.05) and chronic cases (43%, 21%, 15%, 3%, respectively, adjusted *p*\<0.05). A significantly lower number of acute cases presented with arthralgia, back pain and limited motion (60%, 32%, 18%, respectively) than subacute (70%, 49%, 26%, respectively, adjusted *p*\<0.05) and chronic cases (79%, 53%, 39%, respectively, adjusted *p*\<0.05). There were significant adjusted differences in fatigue between subacute and chronic cases (adjusted *p* = 0.02), and differences in weight loss between acute and chronic cases (adjusted *p* = 0.03).

10.1371/journal.pone.0205500.t002

###### Symptoms and signs of 2041 brucellosis cases according to clinical stage, Xinjiang, China, 2014.
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                                                Acute (N = 1520)   Subacute (N = 446)   Chronic (N = 75)   Total (N = 2041)   *p* [\*](#t002fn004){ref-type="table-fn"}   Comparisons among groups *(Bonferroni correction)*
  --------------------------------------------- ------------------ -------------------- ------------------ ------------------ ------------------------------------------- ----------------------------------------------------
  Symptoms                                                                                                                                                                
  Fatigue                                       1002 (66)          320 (72)             42 (56)            1364 (67)          0.01                                        Subacute \> Chronic
  Arthralgia                                    911 (60)           313 (70)             59 (79)            1283 (63)          \<0.0001                                    Acute \< Subacute, Chronic
  Sweating                                      824 (54)           242 (54)             39 (52)            1105 (54)          0.93                                        n.s
  Back pain                                     491 (32)           219 (49)             40 (53)            750 (37)           \<0.0001                                    Acute \< Subacute, Chronic
  Lack of appetite                              407 (27)           84 (19)              11 (15)            502 (25)           0.0004                                      Acute \> Subacute, Chronic
  Headache                                      381 (25)           104 (23)             15 (20)            500 (24)           0.48                                        n.s
  Limited motion                                271 (18)           115 (26)             29 (39)            415 (20)           \<0. 0001                                   Acute \< Subacute, Chronic
  Chills                                        237 (16)           61 (14)              12 (16)            310 (15)           0.59                                        n.s
  Myalgia                                       189 (12)           49 (11)              8 (11)             246 (12)           0.65                                        n.s
  Sleep disturbance                             165 (11)           55 (12)              4 (5)              224 (11)           0.19                                        n.s
  Cough                                         175 (12)           21 (5)               2 (3)              198 (10)           \<0.0001                                    Acute \> Subacute, Chronic
  Nausea                                        82 (5)             21 (5)               7 (9)              110 (5)            0.24                                        n.s
  Orchialgia                                    69 (5)             11 (2)               1 (1)              81 (4)             0.08                                        n.s
  Vomitting                                     36 (2)             11 (2)               1 (1)              48 (2)             0.96                                        n.s
  Abdominal pain                                17 (1.1)           7 (1.6)              4 (5.3)            28 (1.4)           0.02                                        n.s
  Signs                                                                                                                                                                   
  Fever[^†^](#t002fn002){ref-type="table-fn"}   1031 (68)          251 (56)             32 (43)            1314 (64)          \<0.0001                                    Acute \> Subacute, Chronic
  Splenomegaly                                  678 (45)           159 (36)             16 (21)            853 (42)           \<0.0001                                    Acute \> Subacute\>Chronic
  Hepatomegaly                                  362 (24)           106 (24)             13 (17)            481 (24)           0.43                                        n.s
  Weight loss                                   313 (21)           76 (17)              7 (9)              396 (19)           0.02                                        Acute \> Chronic
  Joints tenderness                             121 (8)            45(10)               12 (16)            178 (9)            0.03                                        n.s
  Testis swelling                               49 (3)             7 (2)                1 (1)              57 (3)             0.15                                        n.s
  Joints swelling                               29 (2)             14 (3)               5 (7)              48 (2)             0.02                                        n.s
  Lymphadenopathy                               25 (2)             8 (2)                3 (4)              36 (2)             0.25                                        n.s
  Others[¶](#t002fn003){ref-type="table-fn"}    19 (1)             2 (0.4)              1 (1)              22 (1)             0.03                                        n.s

Data are no. (%) of cases, unless otherwise indicated. Percentages may not total 100 because of rounding.

†Fever was defined as axillary and rectal temperature of \>37.3°Cand \>38.3°C, respectively.

¶Include rash (12), joints deformity (4), meningeal irritation (2) and jaundice (1) in acute brucellosis, rash (2) in subacute brucellosis and cardiac murmur (1) in chronic brucellosis.

\*Percentages of cases with each type were compared with a Chi-square test or Fisher's exact test (where 20% cells have expected count less than 5).

n.s: adjusted *p*≥0.05, not significant

Laboratory findings {#sec014}
-------------------

Laboratory findings at admission are shown in [Table 3](#pone.0205500.t003){ref-type="table"}. The most common laboratory findings were high ESR (69%), high CRP (39%), high ALT (33%) and high AST (20%). These abnormal findings more frequently occurred in acute cases than in the other two groups, adjusted *p\<*0.05 ([S1 Fig](#pone.0205500.s004){ref-type="supplementary-material"}). Anemia was more commonly seen in acute cases (26%) than in subacute cases (20%), adjusted *p*\<0.05. Across all patients, the median hemoglobin was 129 g/L (IQR 117--139), median leukocyte count was 5.9×10^9^ cells/L (IQR 4.7--7.1), median lymphocyte count was 2.8×10^9^ cells/L (IQR 2.1--3.7) and median thrombocyte count was 221×10^9^ /L (IQR 175--272). The median CRP and ESR in the total group were 6.6 mg/L (IQR 2.4--20.0) and 28 mm/h (15--46) respectively. A total of 903 of 1925 cases (47%) showed Brucella growth in their blood culture. And the positive rate (53%) in acute cases was significantly higher than in subacute (31%) and chronic groups (19%) (adjusted *p\<*0.0001). The positive rate of SAT of acute and subacute cases gradually decreased along with the progress of the condition after treatment ([S2 Fig](#pone.0205500.s005){ref-type="supplementary-material"}). The results of regular re-examinations after discharge showed that most acute patients laboratory tests improved after treatment ([S3 Table](#pone.0205500.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0205500.t003

###### Laboratory findings of 2041 brucellosis cases according to clinical stage, Xinjiang, China, 2014.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                           Acute\             Subacute\         Chronic\          Total\             *p*[\*](#t003fn004){ref-type="table-fn"}   Comparisons among groups *(Bonferroni correction)*
                                                      (n = 1520)         (n = 446)         (n = 75)          (n = 2041)                                                    
  --------------------------------------------------- ------------------ ----------------- ----------------- ------------------ ------------------------------------------ ----------------------------------------------------
  Haematology                                                                                                                                                              

  Anemia[†](#t003fn002){ref-type="table-fn"}          387 (26)           87 (20)           14 (19)           488 (24)           0.01                                       Acute \> Subacute

  Median Hb (IQR) (g/L)                               128 (116--139)     129 (119--140)    132 (121--142)    129 (117--139)     0.006                                      Acute \< Chronic

  Leukopenia, \<4×10^9^/L                             190 (12)           43 (10)           8 (11)            241 (12)           0.24                                       n.s

  Leukocytosis, \>10×10^9^/L                          91 (6)             18 (4)            4 (5)             113 (6)            0.29                                       n.s

  Median WBC count(IQR)                               5.9 (4.7--7.2)     5.8 (4.7--7.0)    5.9 (4.7--7.1)    5.9 (4.7--7.1)     0.82                                       n.s

  Lymphopenia, \<0.8×10^9^/L                          9 (0.6)            2 (0.5)           0                 11 (0.5)           0.76                                       n.s

  Lymphocytosis, \>4×10^9^/L                          291 (19)           81 (18)           18 (24)           390 (19)           0.49                                       n.s

  Median LYM count(IQR)                               2.8 (2.1--3.7)     2.8 (2.0--3.7)    3.0 (2.3--4.0)    2.8 (2.1--3.7)     0.30                                       n.s

  Thrombocytopenia,\<100×10^9^/L                      57 (4)             19 (4)            3 (4)             79 (4)             0.88                                       n.s

  Median PLT count(IQR)                               221(175--273)      220 (173--269)    225 (193--267)    221 (175--272)     0.42                                       n.s

  Serum biochemistry                                                                                                                                                       

  ALT\>40 U/L                                         568 (37)           99 (22)           8 (11)            675 (33)           \<0.0001                                   Acute \> Subacute\> Chronic

  Median ALT (IQR)                                    36 (23--60)        25 (17--43)       20 (14--30)       32 (21--54)        \<0.0001                                   Acute \> Subacute\> Chronic

  AST\>42 U/L                                         355 (23)           56 (12)           3 (4)             414 (20)           \<0.0001                                   Acute \> Subacute\> Chronic

  Median AST (IQR)                                    28 (20--44)        22 (16--30)       18 (14--25)       26 (18--40)        \<0.0001                                   Acute \> Subacute\> Chronic

  Bilirubin \>18.6 umol /L                            225 (15)           48 (11)           6 (8)             279 (14)           0.03                                       n.s

  Median bilirubin (IQR)                              10.3 (7.2--15.2)   9.9 (7.0--13.4)   9.5 (6.2--13.0)   10.1 (7.1--14.6)   0.01                                       n.s

  Urea nitrogen \>7.14 mmol/L                         48 (3)             20 (4)            6 (8)             74 (4)             0.05                                       n.s

  Median urea nitrogen (IQR)                          4.1 (3.4--5.0)     4.4 (3.5--5.3)    4.5 (3.7--5.1)    4.2 (3.4--5.1)     0.0002                                     Acute \< Subacute

  Creatinine \>124 umol/L                             8 (0.5)            3 (0.7)           0                 11 (0.5)           0.80                                       n.s

  Median creatinine (IQR)                             60 (51--68)        58 (50--66)       59 (51--68)       59 (51--68)        0.03                                       Acute \> Subacute

  Inflammatory markers                                                                                                                                                     

  CRP \>10 mg/L                                       643 /1515(42)      143 (32)          17 (23)           803 (39)           \<0.0001                                   Acute \> Subacute, Chronic

  Median CRP(IQR)                                     7.6 (3.0--21.9)    4.2 (1.3--14.7)   2.3 (0.9--7.6)    6.6 (2.4--20.0)    \<0.0001                                   Acute \> Subacute, Chronic

  ESR elevation[¶](#t003fn003){ref-type="table-fn"}   1088 (72)          280 (63)          43 (57)           1411 (69)          0.0002                                     Acute \> Subacute, Chronic

  Median ESR (IQR)                                    29 (16--46)        26 (12--47)       22 (12--40)       28 (15--46)        0.0015                                     Acute \> Subacute, Chronic

  Bacterial culture and serum-antibody-test                                                                                                                                

  Culture positive                                    758/1426 (53)      131/424 (31)      14/75 (19)        903/1925(47)       \<0.0001                                   Acute \> Subacute, Chronic

  SAT ≥200                                            1394 (92)          419 (94)          69(92)            1882 (92)          0.33                                       n.s

  SAT ≥400                                            996 (66)           261 (59)          38 (51)           1295 (63)          0.002                                      Acute \> Subacute, Chronic

  Median SAT titer(IQR)                               400 (200--400)     400 (200--400)    400 (200--400)    400 (200--400)     0.007                                      Subacute \> Chronic
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are no. (%) of cases, unless otherwise indicated. Percentages may not total 100 because of rounding. Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SAT, standard tube agglutination test;

† Anemia: female and children \<110 g/L, male\<120 g/ L.

¶ESR positive: female\>20 mm/h and male\>15 mm/h.

\*Medians were compared between each group with the Wilcoxon rank sum test. For categorical variables, percentages of cases in each group were compared with Chi-square test or Fisher's exact test (where 20% cells have expected count less than 5).

n.s: adjusted *p*≥0.05, not significant

Focal involvement {#sec015}
-----------------

There was evidence of focal involvement in 1829 cases (90%) (see [Table 4](#pone.0205500.t004){ref-type="table"}). Osteoarticular involvement was the most frequent and occurred in 1380 cases (68%), including peripheral arthritis (57%), spondylitis (20%) and sacroiliitis (2%). Osteoarticular involvement was found to be significantly more frequent in chronic (87%) and subacute (77%) cases compared to acute cases (64%) (adjusted *p\<*0.001).

10.1371/journal.pone.0205500.t004

###### Focal involvements of 2041 brucellosis cases during clinical stage, Xinjiang, China, 2014.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Focal Involvement[†](#t004fn002){ref-type="table-fn"}   Acute\          Subacute (N = 446)   Chronic (N = 75)   Total\          *p*[\*](#t004fn007){ref-type="table-fn"}   Comparisons among groups *(Bonferroni correction)*
                                                          (n = 1520)                                              (N = 2041)                                                 
  ------------------------------------------------------- --------------- -------------------- ------------------ --------------- ------------------------------------------ ----------------------------------------------------
  Osteoarticular                                          970 (64)        345 (77)             65(87)             1380 (68)       \<0.0001                                   Acute \< Subacute, Chronic

      Peripheral arthritis                                823 (54)        288 (64)             56 (75)            1167 (57)       \<0.0001                                   Acute \< Subacute, Chronic

      Spondylitis                                         255 (17)        119 (27)             25 (33)            399 (20)        \<0.0001                                   Acute \< Subacute, Chronic

      Sacroiliitis                                        36 (2)          12 (3)               0                  48 (2)          0.45                                       n.s

  Gastrointestinal                                        804 (53)        213 (48)             25(33)             1042 (51)       0.001                                      Acute, Subacute \>Chronic

  Haematological[∮](#t004fn003){ref-type="table-fn"}      547 (36)        129 (28)             20 (27)            696 (34)        0.0084                                     Acute\>Subacute

  Genitourinary                                           296 (19)        100 (22)             13 (17)            409 (20)        0.34                                       n.s

      Epididymo-orchitis                                  273 /1180(23)   95/338 (28)          13/55 (24)         381/1573 (24)   0.17                                       n.s

      PID[§](#t004fn004){ref-type="table-fn"}             23/340 (7)      5 /108(5)            0                  28 /468(6)      0.11                                       n.s

  Respiratory                                             112 (7)         10 (2)               0                  122 (6)         \<0.0001                                   Acute \> Subacute, Chronic

      Bronchitis                                          90 (6)          2 (0.4)              0                  92 (5)          \<0.0001                                   Acute \> Subacute, Chronic

      Pneumonia                                           15 (1)          1(0.2)               0                  16 (0.8)        0.26                                       n.s

      Pleural adhesions                                   10 (0.7)        6 (1)                0                  16 (0.8)        0.31                                       n.s

  Cardiovascular[\#](#t004fn005){ref-type="table-fn"}     8 (0.5)         5 (1)                0                  13 (0.6)        0.34                                       n.s

  Cutaneous                                               12 (0.8)        2 (0.5)              0                  14 (0.7)        0.13                                       n.s

  CNS[¶](#t004fn006){ref-type="table-fn"}                 4 (0.3)         0                    1(1)               5 (0.3)         0.63                                       n.s

  Uveitis                                                 0               1 (0.2)              0                  1 (0.05)        0.25                                       n.s
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are no. (%) of cases, unless otherwise indicated. Percentages may not total 100 because of rounding.

† Focal involvements not mutually exclusive; some patients had multiple focal involvements.

∮Includes anemia, leukopenia, leukocytosis, lymphopenia, lymphocytosis and thrombocytopenia.

§PID: Pelvic Inflammatory Disease

\# Includes endocarditis (2) and pericarditis (11).

¶ CNS = central nervous system, includes meningitis (4) and myelitis (1).

\* Percentages of cases with each type were compared with Chi-square test or Fisher's exact test (where 20% cells have expected count less than 5).

n.s: adjusted *p*≥0.05, not significant

Gastrointestinal disorders occurred in 1024 (51%) patients and more frequently in acute (53%) and subacute (48%) cases compared to chronic cases (33%) (adjusted *p*\<0.05). Haematological involvement occurred in 696 (34%) patients and more commonly in the acute group (36%) than in the subacute group (28%) (adjusted *p* = 0.01). A total of 24% of male patients had epididymo-orchitis and 6% of female patients suffered from Pelvic Inflammatory Disease (PID). Respiratory involvement was detected in 122 cases (6%), the majority of which (92%) were in acute cases. Most cases of respiratory involvement presented as bronchitis (75%). Cardiovascular involvement occurred in 13 cases (0.6%). Of these, 2 had endocarditis and 11 had pericarditis. Central nervous system (CNS) involvement occurred in 5 cases (0.3%), including meningitis (4 cases) and myelitis (1 case). A total of 14 cases (0.7%) manifested as cutaneous complaints and 1 case was diagnosed as uveitis.

Follow up and outcomes {#sec016}
----------------------

A total of 1321 cases (65% of total cases) responded to our telephone interview more than 450 days after discharge from hospital. This was long enough to observe treatment outcome ([S2 Table](#pone.0205500.s002){ref-type="supplementary-material"}). Of these, 812 cases (61.5%) fully recovered, 499 cases (37.7%) were unresolved and 10 cases (0.8%) died. Unresolved cases were defined as patients with continued symptoms after discharge. In fatal cases, a 56-year-old male farmer died from endocarditis caused by Brucella after about 60 days of illness onset, while other patients died from other diseases. Of the 499 unresolved cases, there were 74 cases (14.8%) still under medical care at the time of follow-up.

Risk factors associated with outcomes {#sec017}
-------------------------------------

### Univariate analysis {#sec018}

In the univariate logistic regression model ([Table 5](#pone.0205500.t005){ref-type="table"}), factors associated with unfavourable outcome of brucellosis were: age ≥45 years (OR = 1.78, 95% CI 1.42--2.23, *p\<*0.01); arthralgia (OR = 1.45, 95% CI 1.15--1.83, *p =* 0.002); back pain (OR = 1.58, 95% CI 1.25--2.00, *p\<*0.01) and joints tenderness (OR = 2.09, 95% CI 1.42--3.08, *p\<*0.01). The risk of poor prognosis increased as illness duration increased. However, cases with fever (OR = 0.77, 95% CI 0.61--0.98, *p =* 0.030), headache (OR = 0.73, 95% CI 0.55--0.95, *p =* 0.021), haematologic involvement (OR = 0.67, 95% CI 0.52--0.86, *p =* 0.002), aminotransferase elevation (OR = 0.74, 95% CI 0.59--0.93, *p =* 0.011), culture positive (OR = 0.67, 95% CI 0.53--0.85, *p =* 0.008) or treatment with doxycycline combined with rifampicin, were more likely to fully recover.

10.1371/journal.pone.0205500.t005

###### Univariate logistic regression analysis of risk factors for unfavourable prognosis of brucellosis cases.

![](pone.0205500.t005){#pone.0205500.t005g}

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                              Recovered cases\   Unresolved cases\   OR          95% CI       *p* [\*](#t005fn002){ref-type="table-fn"}
                                         N = 812            N = 481                                      
  -------------------------------------- ------------------ ------------------- ----------- ------------ -------------------------------------------
  Demographic features                                                                                   

      Male                               648 (80)           365 (76)            0.81        0.62--1.06   0.119

      Age≥45                             333(41)            265 (55)            1.78        1.42--2.23   \<0.0001

      Duration of illness (days)                                                                         

      ≤7                                 139 (17)           53 (11)             Reference                

      \~30                               251 (31)           124 (25)            1.33        0.91--1.96   0.14

      \~90                               294 (36)           189 (38)            1.70        1.17--2.45   0.005

      \~180                              80 (10)            67 (13)             2.20        1.40--3.48   0.0007

      ≥180                               48 (6)             66 (13)             3.40        2.08--5.55   \<0.0001

  Symptoms                                                                                               

      Fatigue                            550 (68)           316 (66)            0.87        0.68--1.10   0.240

      Arthralgia                         470 (58)           317 (66)            1.45        1.15--1.83   0.002

      Sweating                           442 (54)           273 (57)            1.07        0.86--1.35   0.545

      Back pain                          259 (32)           216 (45)            1.58        1.25--2.00   0.0001

      Lack of appetite                   209 (26)           121 (25)            0.94        0.72--1.21   0.611

      Headache                           209 (26)           99 (21)             0.73        0.55--0.95   0.021

      Chills                             128 (16)           65 (14)             0.82        0.59--1.12   0.213

      Myalgia                            101 (12)           66 (14)             1.07        0.76--1.49   0.703

      Sleep disturbance                  87 (11)            56 (12)             1.05        0.74--1.51   0.775

      Cough                              77 (9)             46 (10)             0.91        0.62--1.34   0.626

  Signs                                                                                                  

      Fever†                             542 (67)           296 (62)            0.77        0.61--0.98   0.030

      Weight loss                        169 (21)           90 (19)             0.87        0.66--1.16   0.867

      Joints tenderness                  53 (7)             63 (13)             2.09        1.42--3.08   0.0002

      Testis swelling                    30 (4)             13 (3)              0.81        0.43--1.56   0.534

      Splenomegaly                       517 (63)           350 (73)            1.46        1.14--1.86   0.002

      Hepatomegaly                       209 (26)           101 (21)            0.76        0.63--1.08   0.154

  Laboratory findings                                                                                    

      Haematologic involvement           265 (33)           120 (25)            0.67        0.52--0.86   0.002

      CRP \>10 mg/L                      332 (41)           188 (39)            0.88        0.69--1.12   0.289

      ESR elevation                      567 (70)           332 (69)            0.92        0.69--1.21   0.531

      Aminotransferase elevation         352 (43)           173 (36)            0.74        0.59--0.93   0.011

      Culture positive                   402 (52)           197 (42)            0.67        0.53--0.85   0.008

      SAT ≥400                           518 (64)           322 (65)            1.05        0.83--1.33   0.676

  Treatment                                                                                              

  Doxycycline+Rifampicin                 420 (52)           228 (47)            0.71        0.52--0.95   0.022

  Doxycycline+Rifampicin+ Levofloxacin   244 (30)           143 (30)            0.79        0.54--1.03   0.076

  Other regimens                         148 (18)           110 (23)            Reference                
  --------------------------------------------------------------------------------------------------------------------------------------------------

Data are no. (%) of cases, unless otherwise indicated. Percentages may not total 100 because of rounding. Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Fever was defined as axillary and rectal temperature of \>37.3°Cand \>38.3°C, respectively.

\*Medians were compared between recovered cases and unresolved cases with the Wilcoxon rank sum test. For categorical variables, percentages of cases in each category were compared with a Chi-square test or Fisher's exact test (where 20% cells have expected count less than 5).

### Multivariate analysis {#sec019}

Multivariate logistic regression analysis was used to identify factors that were independently associated with poor prognosis. Variables with *p\<*0.05 in univariate analysis were included in multivariate analysis ([Table 6](#pone.0205500.t006){ref-type="table"}). We found that fever, headache, arthralgia, aminotransferase elevation, culture positive and initial treatment were no longer significantly (*p*\>0.05) associated with unfavourable prognosis in multivariate analysis.

10.1371/journal.pone.0205500.t006

###### Risk factors for unfavourable prognosis of brucellosis cases, identified by multivariate logistic regression analysis.
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  Variable                                OR          95% CI       *p*
  --------------------------------------- ----------- ------------ ----------
  Age≥45 years                            1.75        1.36--2.24   \<0.0001
  Male                                    0.88        0.66--1.17   0.374
  Duration of illness (days)                                       
      ≤7                                  Reference                
      \~30                                1.43        0.94--2.18   0.095
      \~90                                1.65        1.10--2.46   0.015
      \~180                               1.75        1.06--2.88   0.029
      ≥180                                2.99        1.75--5.10   \<0.0001
  Fever                                   0.90        0.69--1.17   0.431
  Headache                                0.76        0.56--1.01   0.059
  Arthralgia                              1.24        0.95--1.61   0.117
  Back pain                               1.50        1.16--1.94   0.002
  Joints tenderness                       1.73        1.13--2.65   0.011
  Haematologic involvement                0.60        0.45--0.79   0.0003
  Aminotransferase elevation              1.01        0.78--1.32   0.920
  Culture positive                        0.81        0.63--1.05   0.111
  Initial treatment                                                
    Doxycycline+Rifampicin                0.88        0.64--1.22   0.450
    Doxycycline+Rifampicin+Levofloxacin   0.84        0.59--1.19   0.332
    Other regimens                        Reference                

OR odds ratio, CI confidence interval, statistic significant results are bold (p≤0.05).

We observed that age\>45 years (OR = 1.75, 95% CI 1.36--2.24, *p\<*0.001), back pain (OR = 1.50, 95% CI 1.16--1.94, *p =* 0.002) and joint tenderness (OR = 1.73, 95% CI 1.13--2.65, *p =* 0.011) were strongly predictive of poor outcome. Compared with cases who were treated within one week after onset, patients treated more than one week but less than one month after onset were not significantly distinguishable in prognosis. Patients who received treatment for longer than one month after onset were more likely to receive a poor prognosis: 1--3 months (OR = 1.65, 95% CI 1.10--2.46, *p =* 0.015), 3--6 months (OR = 1.75, 95% CI 1.06--2.88, *p =* 0.029), longer than 6 months (OR = 2.99, 95% CI 1.75--5.10, *p\<*0.001). Brucellosis cases with abnormal haematologic findings at admission had a better clinical outcome (OR = 0.60, 95% CI 0.45--0.79, *p\<*0.001).

Discussion {#sec020}
==========

This study retrospectively collected data from the medical records of 2041 patients with laboratory confirmed brucellosis and followed up their clinical outcomes. The clinical features of human brucellosis were described and risk factors for unfavorable prognosis were assessed systematically. The results from this study provide a theoretical basis for clinical diagnosis, treatment and case management of human brucellosis.

The gender and age distributions were consistent with previous studies \[[@pone.0205500.ref005], [@pone.0205500.ref013]\]. A total of 87% of children under 15 years of age presented as acute cases, which suggests that children seek medical advice earlier than adults, or they have more symptoms with infection than adults and are therefore more likely to present to hospital earlier. Or children may be less likely to have localized infections, which may not present as rapidly. The primary transmission route of brucellosis in our study was through occupational exposure (97%), which is in accord with the results of epidemiologic investigations in China \[[@pone.0205500.ref003], [@pone.0205500.ref015]\]. In other endemic countries, infections occur mostly due to ingestion of unpasteurized dairy products \[[@pone.0205500.ref016], [@pone.0205500.ref017]\].

In our study, the most common clinical manifestations of human brucellosis were fatigue (67%), fever (64%), arthralgia (63%) and sweating (54%), of which the rate was lower than that reported by the WHO \[[@pone.0205500.ref018]\]. We found that patients in different clinical stages presented with different clinical features. Systematic manifestation, such as fever, lack of appetite and weight loss, were more frequent in acute cases, while arthralgia, back pain and joint tenderness occurred more frequently in patients with longer disease durations. Similar findings have been described in a study done in Turkey \[[@pone.0205500.ref019]\].

Elevated liver enzymes, increased CRP and increased ESR were the most common laboratory findings seen in our series, especially in acute cases (see *[Table 3](#pone.0205500.t003){ref-type="table"}*). Buzgan et al. reported similar results \[[@pone.0205500.ref019]\]. Along with increased illness duration, we found that both the positive rates of SAT and blood culture fell. This suggests that we should use tests with higher sensitivity to diagnose subacute and chronic cases to avoid missed diagnosis. ELISA, PCR, Coombs test and bone marrow culture may be good choices for subacute and chronic patients, especially for those who have used antibiotics \[[@pone.0205500.ref020], [@pone.0205500.ref021]\].

In our study, osteoarticular involvement was observed in 64% of acute cases, 77% of subacute cases and 87% of chronic cases. This is higher than that reported by Buzgan et al. \[[@pone.0205500.ref019]\]and Hasanjani et al.\[[@pone.0205500.ref022]\]. A study done in Iran showed that sacroilitis (75.7%) was more common than spondylitis (21.4%) and peripheral arthritis (8.6%) \[[@pone.0205500.ref023]\], while a survey done in Turkey found that peripheral arthritis (56.5%) occurred more frequently than sacroilitis (24.6%) and spondylitis (12.3%)\[[@pone.0205500.ref019]\]. Our study indicated that peripheral joints (57%) were more likely to be affected by Brucella than spine (20%) and sacroiliac joints (2%).

A total of 122 patients (6%) showed evidence of respiratory involvement, which mainly manifested as acute infection (92%) with no chronic cases. This is consistent with another report done in Turkey \[[@pone.0205500.ref023]\]. This suggests that respiratory involvement mainly occurred in acute cases. However, the 75% of cases with respiratory abnormalities presented as bronchitis in our series, while pneumonia (68.4%) and pleural effusion (30.8%) were more commonly found in Turkey \[[@pone.0205500.ref024]\].

In some studies from Iran, the recovery rate of human brucellosis has been reported between 80.6% \[[@pone.0205500.ref025]\] and 89.49% \[[@pone.0205500.ref026]\], which is higher than that found in our study (61.5%). In the Sixth People\'s Hospital, many referral patients were received. Therefore, a more severe disease population with a greater risk of poor prognosis may have been included in the current study. A small amount of research has been done on the factors that influence prognosis of human brucellosis. In our study, we identified five independent factors that influenced whether a patient with human brucellosis received a poor prognosis: age ≥45 years, back pain, joint tenderness, long duration of illness and haematologic involvement.

Brucellosis in older patients increases the risk of poor prognosis because these patients often have some immune system dysfunction \[[@pone.0205500.ref027]--[@pone.0205500.ref029]\]. Other studies, however, did not find differences in outcomes according to patient age \[[@pone.0205500.ref026], [@pone.0205500.ref030]\]. In our series, patients aged ≥45 years were more likely to have unfavorable prognosis. We also found that back pain and joint tenderness were associated with increased risk of poor prognosis, which is consistent with Wu's finding \[[@pone.0205500.ref031]\].

Moreover, patients who had brucellosis over a longer duration were more likely to have unfavorable prognosis after treatment. Indeed, Alavi and colleagues reported that the majority of patients who relapse had a prolonged duration of time between the appearance of symptoms and initiation of treatment \[[@pone.0205500.ref032]\]. Although abnormal haematologic findings have previously been shown to be a marker of poor prognosis \[[@pone.0205500.ref030], [@pone.0205500.ref033]\], we present the opposite result (OR = 0.60, 95% CI 0.45--0.79, *p =* 0.003). This may be because those who had abnormal haematologic findings were more likely to present as acute cases in our series, and acute cases tend to have a lower rate of poor outcomes. Therefore, this association could be spurious. More research is needed in this area.

Previous meta-analyses have reached different conclusions regarding the preferred regimens for brucellosis \[[@pone.0205500.ref034], [@pone.0205500.ref035]\]. Generally, dual or triple regimens are advisable. In our series, multivariate analyses showed no significant differences between each combination therapy. However, since the data on real treatment duration and patient compliance after discharge were insufficient, this conclusion about the association between regimens and treatment outcome is substantially underpowered. This would need to be further investigated in a prospective study.

Our study was limited to available data of brucellosis cases identified through retrospective analysis. Cases included in this study were all from a provincial tertiary hospital, where many severe patients were referred. This might explain why the recovery rate observed in our series is lower than that identified in previous studies. Clinical management was uncontrolled, pathological data and medication compliance data were not available, and relapse and reinfection were hard to distinguish from treatment failure. Any differences in outcome cannot be interpreted to be due to the use of antibiotics since there are no clear diagnostic criteria for measuring real cure, and telephone follow-up may decrease the validity of the findings.

In summary, brucellosis cases have a high rate of chronicity. The longer the illness duration, the more difficult brucellosis is to cure. To improve the clinical management of brucellosis in China, early diagnosis and treatment should be of high priority. Age ≥45 years, back pain, and joint tenderness are risk factors of adverse prognosis of brucellosis. Longer courses of treatment should be considered for older patients and those with osteoarticular involvement. The positive rate of blood culture and SAT may gradually decrease with the progress of the condition. Therefore, sensitive diagnostic methods should be used to identify subacute and chronic brucellosis cases to avoid missed diagnosis. Brucellosis patients may show different characteristics in different clinical stages: abnormal laboratory findings and respiratory involvement may be more frequent in acute cases, osteoarticular involvement may be more frequent in subacute and chronic cases.
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